NBIX
Neurocrine Biosciences, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$173.00+1.24%
Price as of Jul 20, 2026
NBIX profitability
Neurocrine Biosciences, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 98.2%
- EBITDA margin
- 30.8%
- EBIT margin
- 25.2%
- Net margin
- 21.6%
- Free cash flow margin
- 26.8%
Returns
- Return on equity
- 19.6%
- Return on assets
- 13.6%
- Return on invested capital
- 20.5%
- Asset turnover
- 0.65x
Cash efficiency
- Cash from operations
- $863.7M
- Cash per share
- $13
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.